Study of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In Spain
NCT01750658 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99
Last updated 2012-12-17
Summary
ECOS is a cross-sectional, observational, longitudinal, multicenter study enrolling 100-200 patients during a COPD exacerbation.
Conditions
Sponsors & Collaborators
-
Hospital Son Espases
collaborator OTHER -
HOSPITAL DOCE DE OCTUBRE
collaborator UNKNOWN -
Hospital Clinic of Barcelona
collaborator OTHER -
Germans Trias i Pujol Hospital
collaborator OTHER -
Hospital Universitario Fundación Jiménez Díaz
collaborator OTHER -
HOSPITAL LA FE VALENCIA
collaborator UNKNOWN -
Hospital de Galdakao
collaborator OTHER -
Hospital del Mar
collaborator OTHER -
Cimera
lead NETWORK
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-09-30
- Primary Completion
- 2009-12-31
- Completion
- 2009-12-31
Countries
- Spain
Study Locations
More Related Trials
-
CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases
NCT05546606 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD
NCT02209974 ·Status: COMPLETED ·Phase: PHASE4
-
Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy
NCT01091493 ·Status: COMPLETED ·Phase: PHASE4
-
Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation
NCT01381458 ·Status: COMPLETED
-
Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment
NCT01395875 ·Status: COMPLETED
-
Impulse Oscillometry in COPD Exacerbation
NCT07185581 ·Status: COMPLETED
-
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
NCT01393145 ·Status: WITHDRAWN ·Phase: PHASE3
-
Treatment and Exacerbation in COPD Subjects
NCT03375450 ·Status: COMPLETED
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00676052 ·Status: COMPLETED ·Phase: PHASE2
-
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01204034 ·Status: COMPLETED ·Phase: PHASE3
-
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
NCT01978145 ·Status: COMPLETED ·Phase: PHASE3
-
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
NCT00950807 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT02299375 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
NCT02130193 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients
NCT01344655 ·Status: COMPLETED ·Phase: PHASE4
-
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.
NCT06321731 ·Status: COMPLETED
-
Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD
NCT01213693 ·Status: COMPLETED ·Phase: NA
-
Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD
NCT02477397 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD
NCT02330952 ·Status: COMPLETED ·Phase: PHASE4
-
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
NCT06334575 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.
NCT05342558 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of COPD Standardized Management on COPD Exacerbation
NCT04664491 ·Status: RECRUITING ·Phase: NA
-
Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease
NCT01599871 ·Status: COMPLETED ·Phase: PHASE3
-
A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01725139 ·Status: COMPLETED ·Phase: PHASE1